Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

[1]  E. Shpall,et al.  Predictors of Veno-Occlusive Disease (VOD) of the Liver in Patients Treated with Inotuzumab Ozogamicin (InO) Containing Regimen in B-Cell Acute Lymphoblastic Leukemia , 2022, Blood.

[2]  E. Clappier,et al.  Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study , 2022, Blood.

[3]  S. Raffel,et al.  Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols , 2022, Blood.

[4]  G. Lenz,et al.  Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) , 2022, Blood.

[5]  G. Garcia-Manero,et al.  Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. , 2022, The Lancet. Haematology.

[6]  B. Wood,et al.  SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Leongamornlert,et al.  Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials , 2021, Haematologica.

[8]  A. Logan,et al.  Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  E. Jabbour,et al.  Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms , 2021, Leukemia.

[10]  S. Behjati,et al.  Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. , 2021, Blood.

[11]  C. Mullighan,et al.  Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. , 2020, The Lancet. Haematology.

[12]  H. Kantarjian,et al.  Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions , 2020, Journal of Hematology & Oncology.

[13]  R. Larson,et al.  Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study , 2019, Cancer.

[14]  M. Liedtke,et al.  Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study , 2019, Cancer.

[15]  I. Aldoss,et al.  Acute Lymphoblastic Leukemia in the Older Adult. , 2019, Journal of oncology practice.

[16]  Shuling Li,et al.  Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL , 2018, Leukemia & lymphoma.

[17]  A. Logan,et al.  Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts , 2018, American journal of hematology.

[18]  M. Konopleva,et al.  Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage , 2018, Cancer.

[19]  C. Pui,et al.  Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia , 2018, JAMA oncology.

[20]  M. Konopleva,et al.  Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[21]  C. Rizzari.  Inotuzumab ozogamicin in older patients with acute lymphoblastic leukaemia: premises and promises. , 2018, The Lancet. Oncology.

[22]  M. Konopleva,et al.  Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial , 2017, JAMA oncology.

[23]  W. Stock,et al.  Management of important adverse events associated with inotuzumab ozogamicin: expert panel review , 2018, Bone Marrow Transplantation.

[24]  Megan E. McNerney,et al.  Therapy-related myeloid neoplasms: when genetics and environment collide , 2017, Nature Reviews Cancer.

[25]  M. Geyer,et al.  Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. , 2017, Blood.

[26]  Erika J. Thompson,et al.  Pre-leukemic clonal hematopoiesis and the risk of therapy-related myeloid neoplasms: a case-control study , 2016, The Lancet. Oncology.

[27]  N. Gökbuget.  Treatment of older patients with acute lymphoblastic leukemia. , 2016, Hematology. American Society of Hematology. Education Program.

[28]  R. Larson,et al.  Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies , 2016, Cancer.

[29]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[30]  Xuelin Huang,et al.  Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia , 2016, British journal of haematology.

[31]  H. Kantarjian,et al.  Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia , 2008, Cancer.